STOCKWATCH: Reasons to be tearful

Last week was a bad week all round for investors in pharma and biotech. It wasn't only the seasonal affective disorder of quarterly reporting. It was more that, judging by share price movements, investors seemed to miss many of the good news stories buried amongst the results. And they missed bad news stories, too. And then they got confused about which was which.

Last week was a bad week all round for investors in pharma and biotech. It wasn't only the seasonal affective disorder of quarterly reporting. It was more that, judging by share price movements, investors seemed to miss many of the good news stories buried amongst the results. And they missed bad news stories, too. And then they got confused about which was which.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapeutic Category

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By 

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.